FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206817> ?p ?o ?g. }

• W4387206817 endingPage "e460" @default.
• W4387206817 startingPage "e460" @default.
• W4387206817 abstract "Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) tract is rare and long-term outcomes are not well defined. Combined modality therapy (CMT) with radiotherapy (RT) in addition to systemic therapy in this setting is not commonly pursued. We aim to characterize outcomes in patients with GI DLBCL treated with systemic therapy, with or without RT.Patients diagnosed with DLBCL of the GI tract (with or without mesenteric involvement) treated at a single institution from 1988-2022 were retrospectively reviewed on an IRB-approved protocol. Clinical and treatment data were collected including adverse events (AE; acute vs late defined as before or 4 weeks after therapy end). Kaplan-Meier and Cox regression models were used to estimate survival.Of 207 patients, 62% were male and median age at diagnosis was 63 (IQR 52-73). Gastric involvement was most common (n = 130, 63%), followed by small intestines (n = 48, 23%) and colon/rectum (n = 24, 12%). Most presented with early-stage disease (n = 124, 60%), with a median IPI score of 1. All patients received chemotherapy. Of 182 treated with CHOP/EPOCH, 36 (20%) were treated in the pre-rituximab era while 146 (80%) received rituximab. 66 patients (32%) were treated with RT, 89% as part of first line CMT. 50 cases (76%) received consolidative RT, while 10 (15%) targeted residual gross disease and 4 (6%) targeted distant sites. Median dose and fractionation were 36Gy (IQR 30.6-39.6) in 18 fractions (IQR 17-22). Over half (n = 132, 64%) developed grade 3+ acute chemotherapy AEs, and the most common were anemia (n = 64), febrile neutropenia (n = 40), and neutropenia (n = 20). Grade 3+ late chemotherapy AEs occurred in 14 patients (7%). Acute grade 3+ radiation AEs were uncommon (n = 2, 3%; colitis, emesis). No grade 3+ late radiation AEs were noted. Median follow-up was 46 months (IQR 16-97). 169 (81.6%) had a complete response (CR), with 154 (91%) after first line chemotherapy, 9 (5%) after second line, and 6 (4%) after RT. CR was defined by PET (62%), endoscopy (22%), CT (9%), or other methods (7%). The 5-year progression-free survival for those treated with one line of chemotherapy with or without RT was 95%. Median overall survival (OS) was not reached. Improved OS was associated with early-stage disease (p = 0.003), low IPI (p = 0.001), fewer chemotherapy lines (p<0.001), and CR (p<0.001). OS did not differ by gender, age, immunophenotype, GI site, SUVmax, or RT. Patients with early stage DLBCL treated with RT in the post-rituximab era received fewer chemotherapy cycles compared to those treated without RT (p = 0.02; median of 4 (IQR 3-6) vs 6 cycles (IQR 4-6)), with no OS difference.GI DLBCL patients have favorable outcomes after CMT with minimal late toxicity. CMT with RT to the GI tract is well tolerated with no OS difference compared to chemotherapy alone, and may mitigate risks from additional chemotherapy cycles for selected early-stage patients." @default.
• W4387206817 created "2023-09-30" @default.
• W4387206817 creator A5007688820 @default.
• W4387206817 creator A5009933533 @default.
• W4387206817 creator A5010407419 @default.
• W4387206817 creator A5011388011 @default.
• W4387206817 creator A5021496101 @default.
• W4387206817 creator A5027886510 @default.
• W4387206817 creator A5028677309 @default.
• W4387206817 creator A5031498320 @default.
• W4387206817 creator A5037180937 @default.
• W4387206817 creator A5037878906 @default.
• W4387206817 creator A5038196228 @default.
• W4387206817 creator A5039574726 @default.
• W4387206817 creator A5043562939 @default.
• W4387206817 creator A5045724173 @default.
• W4387206817 creator A5054301773 @default.
• W4387206817 creator A5069043926 @default.
• W4387206817 creator A5070881206 @default.
• W4387206817 creator A5070923889 @default.
• W4387206817 creator A5083226997 @default.
• W4387206817 date "2023-10-01" @default.
• W4387206817 modified "2023-10-04" @default.
• W4387206817 title "Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract" @default.
• W4387206817 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1655" @default.
• W4387206817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785475" @default.
• W4387206817 hasPublicationYear "2023" @default.
• W4387206817 type Work @default.
• W4387206817 citedByCount "0" @default.
• W4387206817 crossrefType "journal-article" @default.
• W4387206817 hasAuthorship W4387206817A5007688820 @default.
• W4387206817 hasAuthorship W4387206817A5009933533 @default.
• W4387206817 hasAuthorship W4387206817A5010407419 @default.
• W4387206817 hasAuthorship W4387206817A5011388011 @default.
• W4387206817 hasAuthorship W4387206817A5021496101 @default.
• W4387206817 hasAuthorship W4387206817A5027886510 @default.
• W4387206817 hasAuthorship W4387206817A5028677309 @default.
• W4387206817 hasAuthorship W4387206817A5031498320 @default.
• W4387206817 hasAuthorship W4387206817A5037180937 @default.
• W4387206817 hasAuthorship W4387206817A5037878906 @default.
• W4387206817 hasAuthorship W4387206817A5038196228 @default.
• W4387206817 hasAuthorship W4387206817A5039574726 @default.
• W4387206817 hasAuthorship W4387206817A5043562939 @default.
• W4387206817 hasAuthorship W4387206817A5045724173 @default.
• W4387206817 hasAuthorship W4387206817A5054301773 @default.
• W4387206817 hasAuthorship W4387206817A5069043926 @default.
• W4387206817 hasAuthorship W4387206817A5070881206 @default.
• W4387206817 hasAuthorship W4387206817A5070923889 @default.
• W4387206817 hasAuthorship W4387206817A5083226997 @default.
• W4387206817 hasConcept C126322002 @default.
• W4387206817 hasConcept C143998085 @default.
• W4387206817 hasConcept C2778559949 @default.
• W4387206817 hasConcept C2779338263 @default.
• W4387206817 hasConcept C2780653079 @default.
• W4387206817 hasConcept C509974204 @default.
• W4387206817 hasConcept C71924100 @default.
• W4387206817 hasConcept C90924648 @default.
• W4387206817 hasConceptScore W4387206817C126322002 @default.
• W4387206817 hasConceptScore W4387206817C143998085 @default.
• W4387206817 hasConceptScore W4387206817C2778559949 @default.
• W4387206817 hasConceptScore W4387206817C2779338263 @default.
• W4387206817 hasConceptScore W4387206817C2780653079 @default.
• W4387206817 hasConceptScore W4387206817C509974204 @default.
• W4387206817 hasConceptScore W4387206817C71924100 @default.
• W4387206817 hasConceptScore W4387206817C90924648 @default.
• W4387206817 hasIssue "2" @default.
• W4387206817 hasLocation W43872068171 @default.
• W4387206817 hasLocation W43872068172 @default.
• W4387206817 hasOpenAccess W4387206817 @default.
• W4387206817 hasPrimaryLocation W43872068171 @default.
• W4387206817 hasRelatedWork W1598567296 @default.
• W4387206817 hasRelatedWork W1996279342 @default.
• W4387206817 hasRelatedWork W2020184844 @default.
• W4387206817 hasRelatedWork W2031558687 @default.
• W4387206817 hasRelatedWork W2086553216 @default.
• W4387206817 hasRelatedWork W2096774443 @default.
• W4387206817 hasRelatedWork W2344519974 @default.
• W4387206817 hasRelatedWork W2899250601 @default.
• W4387206817 hasRelatedWork W3031222282 @default.
• W4387206817 hasRelatedWork W3031860663 @default.
• W4387206817 hasVolume "117" @default.
• W4387206817 isParatext "false" @default.
• W4387206817 isRetracted "false" @default.
• W4387206817 workType "article" @default.